In vitro treatment of HepG2 with MEK1/2 specific inhibitor U0126 resulted in cell cycle arrest, inhibited expression of cyclin D1, Cdc-2 and Cdk-2 and caused hypophosphorylation of pRB at Ser780 and Ser795.